Background: Excentral cleavage of ␤-carotene to retinoids and apocarotenoids occurs in vitro and in animal models. Whether it occurs in humans is unclear. Objective: We tested the hypothesis of whether humans can cleave ␤-carotene excentrally. Design: A healthy man was given an oral dose of all-trans [10,10Ј,11,11Ј-14 C]-␤-carotene (1.01 nmol; 100 nCi). Its fate and that of its metabolites were measured in serial plasma samples. Its fate in feces and urine was also measured over time. Selected plasma samples were spiked with reference standards of retinol, ␤-apo-
INTRODUCTION
Plants and algae synthesize ␤-carotene that contributes to their color and may confer health benefits as part of diets rich in fruit and vegetables. Approximately 600 carotenoids occur naturally, but only ͨ60 are found in foods commonly consumed by humans (1) . Of these, ␤-carotene is the best known because, pursuant to its central cleavage to retinal and oxidation to retinol, it can serve as an important source of vitamin A. Excentral cleavage of ␤-carotene to retinoids and apocarotenoids has been shown in a variety of in vitro systems and animal models. Whether excentral cleavage occurs in vivo in humans and, if so, to what extent is unclear.
When cleaved centrally by ␤,␤-carotene-15,15Ј-oxygenase [EC 1.13.11.21] (BCO1), ␤-carotene can yield 2 molecules of retinal (2) . When cleaved excentrally, it can lead to 8Ј-, 10Ј-, and 12Ј-apo-carotenals and corresponding alcohols and acids (3) . The enzyme ␤,␤-carotene-9Ј,10Ј-oxygenase (BCO2) was already identified (4) . ␤-Carotene and its derivatives may have activity (4) aside from vitamin A. These biological activities may include modulating immune response, cellular differentiation, and singlet oxygen quenching (5) (6) (7) . Therefore, quantification of ␤-carotene metabolism is paramount to establish its full potential.
Quantifying ␤-carotene metabolism in the context of fractional absorption, accretion, degradation, and elimination is complex because it can be influenced by the individual consumer, the food matrix, and the consumer-food matrix interactions (8) . Previous radioisotope studies estimated intestinal absorption of ␤-carotene and its conversion to retinyl esters (REs) and to retinal that is subsequently oxidized to retinol (9, 10) . However, the conversion of ␤-carotene by BCO2 to other metabolites, such as ␤-apo-8Ј-, 10Ј-, 12Ј-, and 14Ј-carotenals, and retinoic acids (RAs), remains to be determined. Access to accelerator mass spectrometry (AMS) that can measure attomole amounts (1 in 10 Ҁ18 parts) of 14 C (11) enabled us to conduct a feasibility study that tested the hypothesis of whether a healthy man can derive 14 C-retinoids and 14 C-apocarotenoids from a true tracer oral dose of all-trans [10,10Ј,11,11Ј- 14 C]-␤-carotene (1.01 nmol; 543 ng; 100 nCi). The radiation exposure is low, Ȃ 200 nseivert.
Therefore, the metabolic fate in a free-living healthy man of 14 C-␤-carotene administered as an oral dose (1.01 nmol; 543 ng; 100 nCi) in a banana milkshake was determined. The fractional absorption, as well as the metabolic fate and elimination of 14 C-␤-carotene, was also measured in the present study.
SUBJECT, MATERIALS, AND METHODS

Chemicals
All chemicals were checked for 14 C content by AMS before use. Tributyrin (glycerol tributyrate) was obtained from MP Biomedical (Aurora, OH). All solvent and chemicals used, unless otherwise noted, were obtained from Fisher Scientific (Santa Clara, CA). ␤-Carotene and all-trans-retinol, retinyl palmitate, all-trans-RA, 13-cis-RA standards were obtained from Sigma Chemicals (St Louis, MO). The ␤-apo-8Ј-carotenal standard was from Fluka (Buchs, Switzerland), and ␤-apo-12Ј-carotenal, 9-cis-␤-carotene, 13-cis-␤-carotene, and ␤-carotene-5,6-epoxide standards were obtained from Carotenature (Lupsingen, Switzerland). Groceries were purchased at a local supermarket.
Dose preparation
The purity of the all-trans- [10,10Ј,11,11Ј- 14 C]-␤-carotene was checked by reverse-phase HPLC (RP-HPLC) as previously described (12) . The dose (1.01 nmol; 543 ng; 100 nCi) was suspended in 1 mL ethanol. Specific activity was 98.8 Ci/mol. Dose formulation was calculated with the use of a liquid scintillation counter (model 1410; Wallac Oy, Turku, Finland). Radiochemical purity was 99%. A shake that consisted of a whipped mixture of banana, skim milk, and sucrose was prepared and divided between 2 plastic cups. The dose suspended in ethanol was layered over the shake in the first cup. The shake in the second cup was then layered atop that in the first cup as described previously (13) . The entire shake was consumed immediately. The first cup was rinsed with water, and the water was then consumed to ensure that the entire dose was ingested. The quantity of dietary ␤-carotene administered (0.543 g 14 C-␤-carotene plus Ȃ40 g ␤-carotene from the shake) was much smaller than that ingested in a carotene-rich meal.
Subject, diet, and specimen collections
The volunteer was a healthy, nonsmoking man aged 30 y with a body mass index (in kg/m 2 ) of 24.5 who had a normal complete blood count and lipid panel. The subject was instructed to avoid foods with high carotenoid content. A food diary was recorded beginning the week before the study and continuing for 2 wk after dosing, to ensure minimum intake of provitamin A carotenoids and vitamin A. Meals were provided on the day of dose administration to monitor for time and content. Lunch and dinner were served 5.5 and 10 h after dosing; they consisted of a frozen entrée (Amy's Kitchen Inc, Petaluma, CA), choice of apple or banana, and a chocolate chip cookie (Pepperidge Farm Inc, Norwalk, CT). Meals were selected to deliver 30% fat and minimum vitamin A and carotenoid content.
At 0700 on the day the dose was administered, the (fasting) subject was fitted with an intravenous catheter in a forearm vein, and a blood sample was drawn for baseline values just before dosing. Additional blood samples were collected at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 24 , and 36 h after dose delivery. Subsequent blood samples were collected on days 2, 3, 4, 5, 6, 9, 11, 13, 18, 26, 33, 40, 47, 61, 75, 89, 103, 117, 138 , and 166 while the subject was in the fasted state. All blood samples were collected in glass K 3 EDTA evacuated tubes (Vacutainer; BD Diagnostics, Franklin, NJ) and immediately put on ice. A complete collection of feces and urine was taken before dosing to establish baseline values. These collections continued for 14 and 21 d, respectively, after the day of dosing. The subject did not have a history of a serious medical condition or of the use of medications that would interfere with carotenoid metabolism.
Written informed consent was obtained from the subject. The University of California, Davis, and the Lawrence Livermore National Laboratory Institutional Review Boards approved the study, which was conducted according to Good Clinical Practice guidelines and the Declaration of Helsinki, version 1989.
Specimen processing
All specimens were processed under yellow light to prevent degradation of carotenoids and retinoids. Plasma was separated from blood on a fixed-speed bench-top centrifuge (Centrific model 228; Fisher Scientific, Tustin, CA; 3300 rpm; 1380 ҂ g, 10 min, 25°C) and stored at Ҁ80°C. Samples were processed under the same conditions as described previously (14) with slight modification. Briefly, fecal samples were collected in polyethylene bags (1-002-59; Fisher Scientific) and homogenized with KOH/2-propanol buffer solution (1:5, wt:vol). Urine samples were collected in amber containers (14-375-115; Fisher Scientific). Representative homogenized samples of feces (50 mL) and urine (15 mL) were stored at Ҁ80°C until they were analyzed further.
Total carbon analysis
Aliquots of urine (75 L), feces (75 L), and plasma (25 L) were lyophilized, wrapped in aluminum foil, and analyzed for total carbon content (15) by using a carbon/nitrogen analyzer (model 1112; Thermo Finnegan, Rodano, Italy). These analyses were conducted at the Division of Agriculture and Natural Resources Laboratory at the University of California, Davis.
Analyte measurements
The approach for isolating ␤-carotene, retinyl esters (REs), retinol, and RAs involved 3 stages. First, plasma analytes were segregated into neutral (␤-carotene, RE, and retinol) and acidextractable (RA) fractions (12) with modification. Second, neutral and acid-extractable fractions were suspended or comingled in the RP-HPLC mobile phase. Third, the mix was loaded on an RP-HPLC column (ES Industries, West Berlin, NJ) to speciate the analytes in the neutral and acid-extractable fractions with an isocratic mobile phase of acetonitrile:1,4-dioxane:2-propanol: triethylamine (792:148:52:2) with 200 mmol ammonium acetate/L in the alcohol component of the mobile phase. Twenty-second fractions were collected from the RP-HPLC column and processed for AMS analysis as described below.
The neutral fraction, which contained the nonpolar compounds, was extracted from plasma as previously described (13) with a slight modification. Briefly, 200 L plasma was deproteinated with 400 L ethanolic KOH (0.25 N). The nonpolar compounds were thrice extracted from the ethanolic KOH with 1 mL hexane each. The extracts were pooled in an amber vial containing 5 L methanol spiked with 0.25% butylated hydroxytoluene (wt:vol). The solvent was evaporated to dryness under argon, and the residue (nonpolar compounds) was resuspended in 100 L HPLC mobile phase.
For the acid-extractable fraction, glacial acetic acid (12 L) was added to the remainder of the deproteinated plasma. Watersaturated ethyl acetate (0.8 mL) was added, the tube was shaken EXCENTRAL CLEAVAGE OF ␤-CAROTENE IN VIVO IN HUMANS and centrifuged (1380 ҂ g for 10 min at 25°C), and the supernatant fluid containing the acid soluble fraction was transferred to a glass tube (Alltech, Deerfield, IL). Water acidified with 10% glacial acetic acid (300 L) was added. The tube was shaken and centrifuged (1380 ҂ g for 10 minutes at 25°C) to separate (float) the ethyl acetate layer that contained the acid-extractable fraction. The ethyl acetate layer was then transferred to an amber screw-top vial containing 5 L methanol and 0.25% butylated hydroxytoluene (wt:vol). The solvent was evaporated to dryness under a stream of argon. The residue that contained the acidextractable fraction was resuspended in 100 L RP-HPLC mobile phase.
The neutrals (described above) were combined or comingled with the acid extractables (described above) in RP-HPLC mobile phase in a total volume of 200 L. A 20-L aliquot of the mix was injected onto the HPLC column to separate the various analytes contained in the neutral and acid-extractable fractions of the plasma. RP-HPLC eluant fractions (20 s) were collected and processed for AMS analysis as described below.
An HPLC system (model 1100; Agilent Technology, Santa Clara, CA) equipped with a quaternary pump, an auto sampler, and a photodiode array detector was set up to search for and isolate both the neutral and acid-extractable metabolites of the administered ␤-carotene. The system was similar to that described previously (16) , with modifications. Briefly, the stationary phase consisted of a Spherisorb ODS2 (3 m; 250 ҂ 4.0 mm) column equipped with titanium frits and a Javelin ODS2 guard column (all: ES Industries). The isocratic mobile phase consisted of acetonitrile:1,4-dioxane:2-propanol:triethylamine (792:148:58:2) with 200 mmol ammonium acetate/L in the alcohol component for 0 -25 min, a linear ramp to 100% 2-propanol for 1 min, and a 20-min regeneration of the initial column conditions. The flow rate was 0.8 mL/min, and the column temperature was 35°C. The HPLC eluent was collected in quartz sample tubes at 20-s intervals for the entire HPLC run.
The system was standardized with 9 reference standards. They included retinol, retinyl palmitate, and retinyl oleate that were monitored at 325 nm; 13-cis-RA and all-trans-RA that were monitored at 351 nm; and ␤-apo-12Ј-carotenal, ␤-apo-8Ј-carotenal, ␤-carotene-5,6-epoxide, and all-trans-␤-carotene that were monitored at 450 nm. The parent compound, 14 C-␤-carotene, and its 14 C-metabolites 14 C-retinol, 14 C-retinyl palmitate, and 14 C-␤-apo-8Ј-carotenal were separated with the use of the above standardized HPLC system.
AMS analysis
The 20-s RP-HPLC eluent fractions described above were processed as previously described (13) , except that a 50-L aliquot of a solution of tributyrin in methanol (40 mg/mL) was used to add exactly 1.2 mg C to each 20-s RP-HPLC fraction, which was then dried under vacuum to remove the mobile phase and methanol. An aliquot of urine was prepared for 14 C analysis by diluting 100 L of the sample with 900 L HPLC-grade water. Aliquots of diluted urine (100 L) and feces (75 L) were placed in quartz tubes and processed as described for the 20-s RP-HPLC fractions. Carbon in the samples was converted to graphite (17) , and the ratio of 14 C to total C was measured at the Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA.
Statistical analysis
The 14 C content in the whole plasma, urine, and feces was plotted as a function of time since dosing, whereas the 14 C content in the HPLC fractions was plotted as a function of retention time. Plotting was performed with ORIGINLAB software (version 7.5; Microcal, Northampton, MA).
RESULTS
A schematic presentation of some possible cleavage pathways and metabolites of all-trans-␤-carotene is shown in Figure 1 . Central cleavage at the 15,15Ј position is the well-established pathway that leads to vitamin A. Cleavage at the 3Ј-4Ј, 5Ј-6Ј, 7Ј-8Ј, and 9Ј-10Ј positions, were it to occur in humans, would lead to ␤-apo-carotenals that may be converted to ␤-apocarotenols, ␤-apo-carotenyl esters, ␤-apo-carotenoic acids, ␤-apo-carotenoyl esters, and the ring-oxidized metabolites (oxo-, hydroxy-, and epoxy-forms).
C in neat plasma
The profile of 14 C in neat plasma by time since dose included 4 peaks, as shown in Figure 2 . Peak A appeared at 0.15 d after dosing and represented Ȃ3% of the dose (100 nCi dose had 1.6 ҂ 10 9 amol 14 C/mg carbon). Peak B appeared at 0.25 d after dosing and represented Ȃ3.6% of the dose. Peak C appeared at 0.5 d and represented Ȃ2.8% of the dose. Peak D appeared on the third day after dosing; it was poorly resolved.
HPLC separation of reference standards
The separation of the 9 reference standards is shown in Figure 3A . Respective retention times for the retinoids were 3.8, 6.5, 7.5, 18.5, and 21.5 min for retinol, 13-cis-RA, all-trans RA, retinyl palmitate, and retinyl stearate. Respective retention times for the carotenoids were 4.6, 5.5, 10.5, and 15.5 min for ␤-apo-12Ј-carotenal, ␤-apo-8Ј-carotenal, ␤-carotene-5,6-epoxide, and all-trans-␤-carotene.
HPLC separation of 14 C analytes in plasma
The 14 C analytes in plasma 0.25 d after administration of 14 C-␤-carotene are shown in Figure 3B . At this time since dosing, the 14 C peaks matched the retention times for ␤-carotene, retinyl palmitate, and retinyl stearate. The 14 C analytes in plasma 0.5 d after administration of 14 C-␤-carotene are shown in Figure 3C . At this time since dosing, the 14 C peaks matched the retention times for retinol and ␤-carotene. The 14 C analytes in plasma 3 d after administration of 14 C-␤-carotene are shown in Figure 3D . At this time since dosing, the first 14 C peak matched the retention times for ␤-apo-8Ј-carotenal, whereas the second 14 C peak that eluted immediately after 17 min did not match that of any of our reference standards. More reference standards are needed to identify this 14 C metabolite. The possibility that the first peak corresponds to ␤-apo-10Ј-carotenal (rather than to ␤-apo-8Ј-carotenal) cannot be ruled out, for lack of that reference standard.
Plasma 14 C-RE and 14 C-retinol by time since dosing
The profiles of 14 C-RE and 14 C-retinol in plasma at all sampling times since dosing are shown in Figure 4 . The rise of a 14 C-RE peak at 0.15 d after dosing represents delivery of the 14 C retinoid from enterocytes to chylomicra, and the descent represents the presence of 14 C-RE in chylomicron remnants as they are taken up by the liver. The rise of 14 C-retinol that began shortly after 0.2 d after dosing represents the handing off of 14 C-RE to 14 C-retinol bound to retinol-binding protein for secretion into plasma.
Plasma 14 C-carotenoids by time since dosing
The plasma profiles of 14 C-␤-carotene and 14 C-␤-apo-8Ј-carotenal are shown in Figure 5 . The 14 C-␤-carotene appeared as 2 broad peaks. The most interesting feature of the 14 C-apo-8Ј-carotenal peak is that, although it was not present at 0.5 d, it was clearly present on the third day after dosing.
Elimination of 14 C in feces
Elimination of the 14 C label in feces appears in Figure 6 . The first collection of feces after dosing accounted for Ȃ35% of the administered 14 C, so the fractional absorption (apparent digestibility) was Ȃ0.65 (1.00 -0.35). Subsequent collections during the next 13 d accounted for an additional 16% of the administered 14 C, so the fractional daily elimination (metabolic fecal loss resulting from biliary excretion of metabolites such as retinoyl ␤-glucoronide) of the label was Ȃ0.0123 (0.16/13). The cumulative elimination of 14 C in feces was 51% of the administered 14 C during the 2-wk period since dosing. FIGURE 1 . A schematic presentation of some possible cleavage pathways and metabolites of all-trans-␤-carotene. BCO1, ␤,␤-carotene-15,15Ј-oxygenase, is the enzyme responsible for the central cleavage, the well-established pathway that leads to vitamin A. BCO2, ␤,␤-carotene-9Ј,10Ј-oxygenase, cleaves at the 9Ј,10Ј position (excentral cleavage). Cleavage at the 3Ј-4Ј, 5Ј-6Ј, 7Ј-8Ј positions, were it to occur in humans, would lead to ␤-apo-carotenals that may be converted to ␤-apo-carotenols, ␤-apo-carotenyl esters, ␤-apo-carotenoic acids, and ␤-apo-carotenoyl esters. Elimination of 14 
C in urine
Elimination of 14 C in urine appears in Figure 7 . In the cumulative collections, Ȃ15.7% of the administered 14 C was eliminated during the first 21 d since dosing. An interesting feature of the elimination per collection line is the peak that appears in the day 4 and day 5 collections. It may represent the elimination of either the 14 C-␤-apo-8Ј-carotenal or the unknown, or both, which were discovered in plasma 3 d after dosing ( Figure 3D ). The first urine collection (0Ҁ12 h since dosing) accounted for 1.1% of the administered dose. The day 4 and day 5 collections accounted for 2.3% and 1.7% of the administered dose, respectively, and each subsequent collection accounted for Ȃ0.2%.
DISCUSSION
A quantitative understanding of ␤-carotene metabolism is of considerable interest because it is cleaved by a sequence-related family of retinal-and apo-carotenal-forming carotenoid oxygenases to retinoids and apo-carotenoids (Figure 1 ) that perform essential biological functions (18, 19) . The best-known of the oxygenases in humans is the BCO1 that cleaves ␤-carotene to vitamin A (2, 20, 21) . A related cleavage enzyme (BCO2) that cleaves ␤-carotene to ␤-apo-carotenals was also identified and characterized (4). BCO2 is widely distributed among human tissue (22) . Another related oxygenase (RPE65) cleaves alltrans-RE to 11-cis-retinol that is isomerized to 11-cis-retinal through the visual cycle (23) . Therefore, central and excentral ␤-carotene cleavage enzymes occur in humans, but the excentral cleavage metabolites have not been reported. Therefore, we tested whether excentral cleavage was demonstrable in vivo in humans.
We administered a small oral tracer dose of 14 C-␤-carotene. The mass of the dose was 1.01 nmol; the typical dietary intake in the United States is 7 mol/d. The small dose and carefully monitored diet ensured steady state conditions with respect to carotenoid metabolism. We quantified the elimination of the dose in feces and urine for 14 and 21 d, respectively, and we searched plasma for 14 C-␤-apo-carotenals with the use of HPLC and AMS.
We found that the percentage of absorption was Ȃ65% of the administered dose, metabolic fecal loss was Ȃ1% of the administered dose per day (Figure 6 ), and urine loss was Ȃ0.75% of the Days after dose Days after dose Percentage of administered dose FIGURE 7. Fraction of the 14 C dose eliminated in urine as a function of time after an oral tracer dose of 14 C-␤-carotene. Cumulative recovery of 14 C (OE) and daily collection (E). bers in the CCD family are found in bacteria, plants, and higher species, and they have been identified with a range of substrate specificities (18) . One plant CCD that has narrow substrate specificity is the maize Vp14 (32); another CCD has broad substrate specificity (AtCCD1) (33) . Therefore, plant and bacterial CCDs can cleave ␤-carotene at several positions that lead to formation of a mix of cyclic and linear apocarotenoids (32, 34 -37) . A search of animals for additional BCOs is an exciting possibility.
The appearance of 14 C-␤-apo-8Ј-carotenal in plasma at 3 d after dosing suggests that ␤-apo-carotenals are formed in peripheral tissues from dietary ␤-carotene that is absorbed from the intestine and already transferred to peripheral tissues-ie, RPE65 (38, 39) . This interpretation is consistent with the fact that the BCO2 is uniquely distributed in muscle cells, connective tissue, and endocrine pancreas, which suggests an alternative function of vitamin A synthesis for BCO2 (22) . Our feasibility study tentatively identified the formation of ␤-apo-8Ј-carotenal and perhaps ␤-apo-8Ј-carotenyl ester or ␤-apo-8Ј-carotenoate by excentral cleavage of ␤-carotene in a normal human. This is a new finding that requires confirmation and, if confirmed, further investigation in additional subjects.
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